The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

NCT02098395 on ClinicalTrials.gov · last registry update 2017-02-09

Finished April 2015, after enrolling 835 people. Primary outcome, as filed: Change From Baseline in Glycosylated Haemoglobin (HbA1c). liraglutide is approved in the US, but not for diabetes and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 835
Started: 2014-05
Primary completion: 2015-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Haemoglobin (HbA1c)

Conditions studied

Diabetes · Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.